# Phase 2a Study of PRV-6527 in Subjects With Moderately to Severely Active Crohn's Disease

> **NCT03854305** · PHASE2 · COMPLETED · sponsor: **Provention Bio, Inc.** · enrollment: 93 (actual)

## Conditions studied

- Crohn's Disease

## Interventions

- **DRUG:** PRV-6527
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03854305
- **Lead sponsor:** Provention Bio, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-03-20
- **Primary completion:** 2019-08-13
- **Final completion:** 2019-08-13
- **Target enrollment:** 93 (ACTUAL)
- **Last updated:** 2021-09-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03854305

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03854305, "Phase 2a Study of PRV-6527 in Subjects With Moderately to Severely Active Crohn's Disease". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT03854305. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*